Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaele Giusti

Showing results (91-100 of 138) with videos related to

Pageof 14
Sort By:
Vaccines|May 2, 2020
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with ImmunotherapyAndrea Botticelli, Alessio Cirillo, Simone Scagnoli, et al.
Frontiers in Oncology|December 7, 2020
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone MetastasesMarta Laganà, Cristina Gurizzan, Elisa Roca, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2022
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)Antonio Passaro, Giuseppe Lo Russo, Francesco Passiglia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2021
KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to ImmunotherapyStefano Scalera, Marco Mazzotta, Giacomo Corleone, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Critical Reviews in Oncology/Hematology|October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trialsDaniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Journal for Immunotherapy of Cancer|August 8, 2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genesMarco Mazzotta, Marco Filetti, Mario Occhipinti, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN studyDario Trapani, Sara J Nidhamalddin, Sara Gandini, et al.
Clinical Lung Cancer|March 20, 2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC PatientsAlessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
Pageof 14

Showing results (91-100 of 138) with videos related to

Sort By:
Pageof 14
Vaccines|May 2, 2020
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with ImmunotherapyAndrea Botticelli, Alessio Cirillo, Simone Scagnoli, et al.
Frontiers in Oncology|December 7, 2020
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone MetastasesMarta Laganà, Cristina Gurizzan, Elisa Roca, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2022
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)Antonio Passaro, Giuseppe Lo Russo, Francesco Passiglia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2021
KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to ImmunotherapyStefano Scalera, Marco Mazzotta, Giacomo Corleone, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Critical Reviews in Oncology/Hematology|October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trialsDaniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Journal for Immunotherapy of Cancer|August 8, 2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genesMarco Mazzotta, Marco Filetti, Mario Occhipinti, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN studyDario Trapani, Sara J Nidhamalddin, Sara Gandini, et al.
Clinical Lung Cancer|March 20, 2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC PatientsAlessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
Pageof 14